Psoriasis

The availability is notable as it introduces the first oral treatment option for young psoriasis patients.

Patients showed significant improvements in skin severity, quality of life, blood pressure, and cardiovascular health, with enhanced psychological well-being.

Researchers suggested that itch control is key in reducing disease burden and improving life quality for patients with psoriasis and atopic dermatitis.

Brenda Kong-Tunac, a patient with PsO, PsA, and skin of color, shares her experiences.

Kindred spoke with Dermatology Times to discuss AbbVie's recent Science of Skin event and improving access to equitable dermatological care.

Researchers linked higher exposure to natural environments and green spaces with an increased risk of developing psoriasis.

Increased COPD prevalence in patients with psoriasis likely reflects smoking correlation, according to researchers.

Psoriasis specialists evaluate strategies for integrating emerging therapies into existing treatment protocols and conclude by addressing persistent gaps in current psoriasis management approaches.

Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.

Both 8-week and 16-week dosing intervals of guselkumab achieved similar clinical outcomes and patient-reported responses in the GUIDE trial.

Alumis' Martin Babler shared insights into the program for the TYK2 inhibitor and the company's next steps for its development.

Skin with vitiligo and psoriasis shows increased immune cell type, with a Mendelian analysis finding no causal link between the conditions.

Researchers suggested that early intervention with less than 2 years of disease duration was associated with a lower risk of relapse.

Clinicians analyze long-term efficacy data in psoriasis treatments, focusing on how they communicate and contextualize information about treatment duration to their patients.

Physicians examine the enduring effectiveness and key findings from the POETYK PSO-1 clinical trials, evaluating their impact on the evolving landscape of psoriasis treatment options.

A recent review called for gender-specific studies to enhance dermatological treatments and potentially revise guidelines.

An expert dermatologist examines the efficacy and potential of tapinarof cream, a novel non-steroidal topical treatment, in providing long-term relief for patients with plaque psoriasis.

A dermatologist explores strategies for managing adverse events in psoriasis treatment, with a specific focus on considerations and best practices for patients with skin of color.

An expert dermatologist explores personalized psoriasis treatment strategies, emphasizing patient education on realistic treatment response expectations and proper application techniques to enhance therapeutic efficacy.

A board-certified dermatologist examines evidence-based strategies for managing plaque psoriasis, focusing on personalized non-steroidal treatment options to optimize patient outcomes.

A recent study found psoriasis content deemed “unreliable” still obtained 850,000 likes.

Medical experts explore approaches for addressing suboptimal outcomes in systemic psoriasis treatments, including methods to enhance therapeutic efficacy and criteria for transitioning to alternative treatments.

Dermatology experts examine the role of IL-17 inhibitors in psoriasis management, focusing on treatment strategies, swift clinical responses, and their effectiveness across various anatomical sites affected by plaque psoriasis.

Researchers behind the phase 3 studies gave pearls into the study methods, results, and what is up next.

The submission to the FDA is supported by positive results from the ARRECTOR phase 3 trial.